Bayer in addition to also Johnson & Johnson Settle Lawsuits Over Xarelto, a Blood Thinner, for $775 Million

Johnson & Johnson in addition to also Bayer said on Monday of which they had agreed to pay $775 million to settle about 25,000 lawsuits involving the blood thinner Xarelto, which they jointly sell.

The settlement, which will be split evenly between the two companies, resolves state in addition to also federal cases in which patients sued the companies for failing to warn about potentially fatal bleeding episodes when patients took the drug.

Neither company admitted liability, in addition to also each noted of which the companies had prevailed inside six lawsuits of which went to trial. In a statement, Janssen, the pharmaceutical division of Johnson & Johnson, said the idea was settling because such complex litigation “demands an enormous amount of time in addition to also resources.” the idea added: “What’s the bottom line? We stand behind Xarelto in addition to also are eager in addition to also excited to move forward.”

In a separate statement, Bayer said, “We remain committed to the more than 45 million patients who have been prescribed Xarelto worldwide.”

“This particular is usually a fair in addition to also just resolution for thousands of consumers who have substantial claims,” Andy Birchfield of Beasley Allen, the co-lead counsel of the plaintiff’s steering committee for the federal legislation, said in a statement.

Xarelto is usually one of a completely new group of blood thinners intended to replace warfarin, a widely used in addition to also decades-old drug of which required frequent blood tests in addition to also a strict diet. Xarelto, along with similar drugs like Eliquis in addition to also Pradaxa, did not require such tests.

Lawyers for the patients had argued of which the companies failed to warn patients of which Xarelto, which thins the blood to prevent clots of which lead to strokes, could trigger massive bleeding in some people, leading to deaths in addition to also serious injury. The bleeding episodes didn’t always respond to standard treatments in addition to also, for years, there was no specific antidote to bleeding caused by Xarelto in addition to also the some other completely new drugs.

Last year, the Food in addition to also Drug Administration approved such an antidote, Andexxa, of which can help stop the bleeding in patients who take Xarelto in addition to also Eliquis, which is usually sold by Pfizer in addition to also Bristol-Myers Squibb.

although Bayer in addition to also Johnson & Johnson stood by Xarelto, citing large-scale clinical trials of which showed the drug was safe in addition to also effective.